Biomedical innovations in the area of molecular diagnostics are the framework for a new golden age of medicine. Unfortunately, a hurdle on the path from discovery to development to delivery could block these life sustaining and life saving innovations from getting to the patient.Continue reading
Category Archives: Health
State of Biomedical Innovation – Global Leaders share ideas at Brookings
On July 16, the Engelberg Center for Health Care Reform at Brookings hosted the second annual State of Biomedical Innovation conference.Continue reading
TGen-TD2-Scottsdale Healthcare breast cancer pilot study shows value of molecular profiling and proteomic mapping
Patients benefit from treatments tailored specifically for their tumor types; stage set for larger studyContinue reading
BioPharm Insight Analysis: Ulthera
Ulthera evaluating exit strategies in wake of turning cash-flow positive – CEO BioPharm InsightContinue reading
Iron Horse Diagnostics partnership for ALS diagnostics on the horizon
Iron Horse Diagnostics partnership for ALS diagnostics on the horizon, raising USD 4m for TBI program
- Two 250-patient TBI trials planned for when funding is in place
- ALS diagnostics validation process to be complete in four months
- Seeking CRO for ALS, and eventually TBI, diagnostics trialsContinue reading
Improving Drug Warning Systems at UA
UA Pharmacists Lead National Effort to Improve Drug Warning Systems. Nearly every pharmacy and hospital in the U.S. relies on drug warning systems, and most physicians soon will, too. Yet such systems still have some weaknesses, which UA pharmacists are working to address.Continue reading
U.S. Food and Drug Administration and European Medicines Agency Reach Landmark Decisions on Critical Path institute’s Clinical Trial Simulation Tool for Alzheimer’s Disease
In a big step forward for Alzheimer’s disease (AD) therapy development, both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have independently reached favorable decisions on the value of Critical Path Institute’s new disease simulation tool for improving trial design in mild and moderate Alzheimer’s disease. The first such instrument to ever receive this regulatory designation, the tool represents an enabling advance to improve the design of future clinical trials in AD. The new tool applies computerized models to simulate “what-if” scenarios for clinical trials.
The goal of this virtual tool is to serve as a public resource for sponsors designing trials of new therapies for AD.Continue reading
FDA Names UA Antivenom Expert Hero of Rare Diseases
For her groundbreaking work on developing treatments for snakebites and scorpion stings, UA physician-scientist Leslie Boyer has been named a Hero of Rare Diseases by the FDA.Continue reading
Calimmune Initiates HIV Stem Cell Study at Two California Research Sites
The HIV gene medicines company, Calimmune, announced today that the first patient has begun treatment in a Phase I/II clinical trial designed to determine whether a pioneering genetic medicine approach can help to protect individuals infected with HIV from the effects of the virus. The study, “Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection,” utilizes a gene medicine called Cal-1, developed in the lab of Nobel Laureate Dr. David Baltimore and by Calimmune.Continue reading